<DOC>
	<DOCNO>NCT01446276</DOCNO>
	<brief_summary>The purpose study investigate potential metabolic effect resveratrol obese healthy men non-alcoholic fatty liver disease . The investigator hypothesize resveratrol : - decrease hepatic very-low-density-lipoprotein-triglyceride ( VLDL-TG ) secretion - decrease liver fat content - increase insulin sensitivity The investigator look change : - lipid turnover ( VLDL-TG kinetics , palmitate kinetics , indirect calorimetry ) - liver fat content ( MR liver spectroscopy ) - insulin sensitivity ( glucose kinetics hyperinsulinaemic euglycaemic clamp ) - body composition ( DXA MRI ) - lipase activity fat cell size ( fat biopsy abdominal femoral adipose tissue )</brief_summary>
	<brief_title>Long-term Investigation Resveratrol Fat Metabolism Obese Men With Nonalcoholic Fatty Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<criteria>Male 2565 year Obesity ( BMI &gt; 28 kg/m2 , waist/hip ratio &gt; 0,95 ) Have nonalcoholic fatty liver disease ( NAFLD ) ( intervention group ) NAFLD ( control group ) May hypertension and/or hypercholesterolemia Written inform consent Any disease NAFLD ( e.g . diabetes , thyroid parathyroid disease , heart , liver kidney disease ) Present previous malignancy Alcohol dependency ( 21 unit alcohol per week ) History smoke Participation study radioactive isotope within last six month Hemoglobin normal range regard sex ( 8.3 mmol/l men )</criteria>
	<gender>Male</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Resveratrol</keyword>
	<keyword>Nonalcoholic fatty liver disease</keyword>
	<keyword>Insulin sensitivity</keyword>
	<keyword>Lipid turnover</keyword>
	<keyword>Liver fat content</keyword>
</DOC>